BioNTech SE (ETR:22UA)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of EUR 21.39 billion. The enterprise value is 6.94 billion.

Market Cap	21.39B
Enterprise Value	6.94B

Important Dates

The last earnings date was Monday, November 3, 2025.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.40%
Shares Change (QoQ)	-1.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.79
PB Ratio	1.16
P/TBV Ratio	1.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-12.14
EV / Sales	2.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.01

Financial Position

The company has a current ratio of 7.12, with a Debt / Equity ratio of 0.01.

Current Ratio	7.12
Quick Ratio	6.89
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.50
Interest Coverage	-54.07

Financial Efficiency

Return on equity (ROE) is -3.04% and return on invested capital (ROIC) is -2.64%.

Return on Equity (ROE)	-3.04%
Return on Assets (ROA)	-2.30%
Return on Invested Capital (ROIC)	-2.64%
Return on Capital Employed (ROCE)	-4.21%
Revenue Per Employee	465,520
Profits Per Employee	-84,406
Employee Count	6,772
Asset Turnover	0.14
Inventory Turnover	2.09

Taxes

In the past 12 months, BioNTech SE has paid 49.40 million in taxes.

Income Tax	49.40M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.91% in the last 52 weeks. The beta is 1.31, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.31
52-Week Price Change	-20.91%
50-Day Moving Average	88.80
200-Day Moving Average	91.43
Relative Strength Index (RSI)	50.97
Average Volume (20 Days)	45,812

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.40

Income Statement

In the last 12 months, BioNTech SE had revenue of EUR 3.15 billion and -571.60 million in losses. Loss per share was -2.38.

Revenue	3.15B
Gross Profit	2.60B
Operating Income	-805.60M
Pretax Income	-522.20M
Net Income	-571.60M
EBITDA	-467.80M
EBIT	-805.60M
Loss Per Share	-2.38

Balance Sheet

The company has 14.53 billion in cash and 245.40 million in debt, giving a net cash position of 14.28 billion.

Cash & Cash Equivalents	14.53B
Total Debt	245.40M
Net Cash	14.28B
Net Cash Per Share	n/a
Equity (Book Value)	18.48B
Book Value Per Share	76.84
Working Capital	13.61B

Cash Flow

In the last 12 months, operating cash flow was -316.80 million and capital expenditures -178.50 million, giving a free cash flow of -495.30 million.

Operating Cash Flow	-316.80M
Capital Expenditures	-178.50M
Free Cash Flow	-495.30M
FCF Per Share	n/a

Margins

Gross margin is 82.49%, with operating and profit margins of -25.55% and -18.13%.

Gross Margin	82.49%
Operating Margin	-25.55%
Pretax Margin	-16.56%
Profit Margin	-18.13%
EBITDA Margin	-14.84%
EBIT Margin	-25.55%
FCF Margin	n/a

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.40%
Shareholder Yield	0.40%
Earnings Yield	-2.67%
FCF Yield	-2.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 6.95 and a Piotroski F-Score of 2.

Altman Z-Score	6.95
Piotroski F-Score	2